Estrella Immunopharma

ESLA · NASDAQ

$0.40+$0.0201 (+5.29%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.3799

Latest news

NewsOct 19, 1:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseOct 15, 6:45 PM ETBusiness Wire
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Press releaseOct 14, 4:15 PM ETBusiness Wire
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
NewsOct 12, 4:29 AM ETAvi Kapoor
Why J-Star Holding Shares Are Trading Higher By Around 128%; Here Are 20 Stocks Moving Premarket
NewsAug 5, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseAug 3, 8:00 AM ETBusiness Wire
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Press releaseJul 29, 8:00 AM ETBusiness Wire
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Press releaseJul 24, 8:00 AM ETBusiness Wire
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
NewsJul 17, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
Press releaseMay 5, 8:00 AM ETBusiness Wire
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
Press releaseMar 23, 8:00 AM ETBusiness Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
NewsMar 10, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseFeb 9, 7:00 AM ETBusiness Wire
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
NewsFeb 6, 12:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsFeb 5, 4:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsFeb 5, 12:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
Press releaseFeb 3, 8:00 AM ETBusiness Wire
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Press releaseJan 6, 2:02 PM ETBusiness Wire
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Press releaseJan 5, 8:30 AM ETBusiness Wire
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Press releaseDec 4, 8:00 AM ETBusiness Wire
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
NewsNov 4, 12:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseNov 3, 8:00 AM ETBusiness Wire
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
Press releaseOct 6, 8:00 AM ETBusiness Wire
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
Press releaseJun 5, 8:00 AM ETBusiness Wire
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
NewsJun 3, 8:07 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseJun 3, 8:00 AM ETBusiness Wire
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
Press releaseMay 29, 8:01 AM ETBusiness Wire
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas
Press releaseMar 5, 8:00 AM ETBusiness Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
Press releaseFeb 21, 8:30 AM ETBusiness Wire
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
Press releaseFeb 19, 4:46 PM ETBusiness Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
NewsOct 30, 4:31 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsSep 30, 8:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsSep 27, 4:31 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
Press releaseSep 27, 12:00 PM ETBusiness Wire
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

12 Health Care Stocks Moving In Monday's Intraday Session

Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase

Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Why J-Star Holding Shares Are Trading Higher By Around 128%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma

12 Health Care Stocks Moving In Friday's Intraday Session

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research

12 Health Care Stocks Moving In Tuesday's After-Market Session

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

12 Health Care Stocks Moving In Tuesday's Intraday Session

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells